Title:
Antitubercular drug resistance in four healthcare facilities in north India

dc.contributor.authorAnamika Gupta
dc.contributor.authorJitendra Prasad Mathuria
dc.contributor.authorSurya Kumar Singh
dc.contributor.authorAnil Kumar Gulati
dc.contributor.authorShampa Anupurba
dc.date.accessioned2026-02-07T05:25:57Z
dc.date.issued2011
dc.description.abstractTuberculosis (TB) is a major public-health problem in India, having the highest number of incident and multidrug-resistant (MDR) TB cases. The study was carried out to appraise the prevalence of first-line anti-TB drug resistance in Mycobacterium tuberculosis (MTB) and its patterns among different types of TB patients from different settings in a province of North India. Of 3,704 clinical specimens, 345 (9.3%) were culturepositive, and drug-susceptibility testing was carried out for 301 MTB strains. A high level of primary and acquired drug resistance of MTB was observed in the region studied, with weighted mean of 10.5% and 28.08%, 12.81% and 29.72%, 17.12% and 29.94%, 11.97% and 27.84%, and 10.74% and 23.54% for rifampicin, isoniazid, streptomycin, ethambutol-resistant and MDR cases respectively. Drug resistance was significantly higher in pulmonary (p=0.014) and acquired drug-resistant TB cases (p<0.001). Any drug resistance (p=0.002) and MDR TB were significantly (p=0.009) associated with HIV-seropositive cases. An urgent plan is needed to continuously monitor the transmission trends of drug-resistant strains, especially MDR-TB strains, in the region. © International Centre for Diarrhoeal Disease Research, Bangladesh.
dc.identifier.issn16060997
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/22314
dc.subjectAcquired immunodeficiency syndrome
dc.subjectAntitubercular drugs
dc.subjectDiabetes
dc.subjectDrug resistance
dc.subjectHIV
dc.subjectIndia
dc.subjectTuberculosis
dc.titleAntitubercular drug resistance in four healthcare facilities in north India
dc.typePublication
dspace.entity.typeArticle

Files

Collections